All links accessed June 3 2019:

1. International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018. 38;1;1–211. https://www.ihs-headache.org/ichd-guidelines

2. World Health Organization. Headache disorders. April 8 2016. https://www.who.int/news-room/fact-sheets/detail/headache-disorders

3. TJ Steiner et al. ‘Migraine: the seventh disabler’. The Journal of Headache and Pain. 2013. 14:1 https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/1129-2377-14-1

4. Lancaster University. ’86 million workdays lost to migraine in the UK every year’. April 27 2018. https://www.lancaster.ac.uk/news/articles/2018/86-million-workdays-lost-to-migraine-in-the-uk-every-year/

5. The Migraine Trust. Facts and figures. https://www.migrainetrust.org/about-migraine/migraine-what-is-it/facts-figures/

6. PJ Goadsby et al. ‘Pathophysiology of Migraine: A Disorder of Sensory Processing’. Physiological Reviews. April 2017. 97;2:553-622. https://www.physiology.org/doi/full/10.1152/physrev.00034.2015

7. ES Kristofferson and C Lundqvist. ‘Medication-overuse headache: epidemiology, diagnosis and treatment’. Ther Adv Drug Saf. April 2014. 5;2:87–99. https://journals.sagepub.com/doi/10.1177/2042098614522683

8. DYT Wei et al. ‘Cluster headache: Epidemiology, pathophysiology, clinical features, and diagnosis’. Annals of Indian Academy of Neurology. 2018. 21;5:3-8. http://www.annalsofian.org/article.asp?issn=0972-2327;year=2018;volume=21;issue=5;spage=3;epage=8;aulast=Wei

9. Work Foundation. ‘Migraine’s impact on employment in Europe - What can be done to improve work outcomes for people with migraine?’. February 2019. http://www.theworkfoundation.com/wp-content/uploads/2019/02/Migraines-impact-on-employment-in-Europe-FINAL-pub.pdfhttp://www.healthdata.org/research-article/global-regional-and-national-burden-migraine-and-tension-type-headache-1990%E2%80%932016

10. LJ Stovner et al. GBD 2016 Headache Collaborators. ‘Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016’. The Lancet Neurology. November 2018. 17;11:954-976. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30322-3/fulltext

11. NHS Digital. Prescription Cost Analysis – England, 2018 [PAS]. March 28 2019. https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018

12. TJ Steiner et al. ‘The impact of headache in Europe: principal results of the Eurolight project’. The Journal of Headache and Pain. 2014. 15:31. https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/1129-2377-15-31

13. NHS. Cluster headaches. Page last reviewed May 22 2017. https://www.nhs.uk/conditions/cluster-headaches/

14. NHS. Migraine. Page last reviewed May 10 2019. https://www.nhs.uk/conditions/migraine/

15. The Migraine Trust. Cluster headache. https://www.migrainetrust.org/about-migraine/types-of-migraine/other-headache-disorders/cluster-headache/

16. T Sprenger et al. ‘Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action’. Neurotherapeutics. April 2018. 15;2:313-323. https://link.springer.com/article/10.1007%2Fs13311-018-0621-8

17. A Straube and A Andreou. ‘Primary headaches during lifespan’. The Journal of Headache and Pain. April 8 2019. 20;35. https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-019-0985-0

18. J Hoffman and A May. ‘Diagnosis, pathophysiology, and management of cluster headache’. The Lancet Neurology. November 23 2017. 17;1:75-83. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30405-2/fulltext

19. A Buture et al. Update on the pathophysiology of cluster headache: imaging and neuropeptide studies. Journal of Pain Research. January 4 2019. 2019;12:269-281. https://www.dovepress.com/update-on-the-pathophysiology-of-cluster-headache-imaging-and-neuropep-peer-reviewed-fulltext-article-JPR

20. American Migraine Foundation. ‘Flushing, Drooping, Tearing, and Stuffiness… Autonomic Symptoms in Headache’. https://americanmigrainefoundation.org/resource-library/flushing-drooping-tearing-and-stuffiness-autonomic-symptoms-in-headache/

21. S Iyengar et al. ‘CGRP and the Trigeminal System in Migraine’. Headache. April 14 2019. 59;5:659-681. https://onlinelibrary.wiley.com/doi/full/10.1111/head.13529

22. MG Waung et al. ‘Metabotropic glutamate receptor 5: a target for migraine therapy’. Annals of Clinical and Translational Neurology. July 1 2016. 3;8: 560-571. https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.302

23. L Edvinsson et al. ‘CGRP as the target of new migraine therapies — successful translation from bench to clinic’. Nat Rev Neurol. June 2018. 14;6:338-350. http://www.readcube.com/articles/10.1038/s41582-018-0003-1

24. Biohaven Pharmaceuticals. Rimegepant.  https://www.biohavenpharma.com/science-pipeline/cgrp/rimegepant

25. Allergan. ‘Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine’. March 11 2019. https://www.allergan.com/news/news/thomson-reuters/allergan-announces-fda-acceptance-of-new-drug-appl

26. NICE. ‘Erenumab for preventing migraine [ID1188]’. Last update May 24 2019. https://www.nice.org.uk/guidance/indevelopment/gid-ta10302

27. Scottish Medicines Consortium/Healthcare Improvement Scotland. erenumab (Aimovig). April 8 2019. https://www.scottishmedicines.org.uk/medicines-advice/erenumab-aimovig-full-submission-smc2134/

28. Lilly. ‘Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache’. November 14 2018. https://investor.lilly.com/news-releases/news-release-details/lilly-submits-new-drug-application-fda-lasmiditan-acute

29. European Medicines Agency. Emgality. February 14 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/emgality

30. European Medicines Agency. Ajovy. April 17 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/ajovy

31. Alder Biopharmaceuticals. Pipeline. Eptinezumab. https://www.alderbio.com/pipeline/eptinezumab/